Literature DB >> 29905850

Predictors of Recurrence, Progression, and Retreatment in Basilar Tip Aneurysms: A Location-Controlled Analysis.

Isaac Josh Abecassis1, Rajeev D Sen1, Jason Barber1, Rakshith Shetty1, Cory M Kelly1, Basavaraj V Ghodke2, Danial K Hallam2, Michael R Levitt1,2,3, Louis J Kim1,2, Laligam N Sekhar1.   

Abstract

BACKGROUND: Endovascular treatment of intracranial aneurysms is associated with higher rates of recurrence and retreatment, though contemporary rates and risk factors for basilar tip aneurysms (BTAs) are less well-described.
OBJECTIVE: To characterize progression, retreatement, and retreated progression of BTAs treated with microsurgical or endovascular interventions.
METHODS: We retrospectively reviewed records for 141 consecutive BTA patients. We included 158 anterior communicating artery (ACoA) and 118 middle cerebral artery (MCA) aneurysms as controls. Univariate and multivariate analyses were used to calculate rates of progression (recurrence of previously obliterated aneurysms and progression of known residual aneurysm dome or neck), retreatment, and retreated progression. Kaplan-Meier analysis was used to characterize 24-mo event rates for primary outcome prediction.
RESULTS: Of 141 BTA patients, 62.4% were ruptured and 37.6% were unruptured. Average radiographical follow-up was 33 mo. Among ruptured aneurysms treated with clipping, there were 2 rehemorrhages due to recurrence (6.1%), and none in any other cohorts. Overall rates of progression (28.9%), retreatment (28.9%), and retreated progression (24.7%) were not significantly different between surgical and endovascular subgroups, though ruptured aneurysms had higher event rates. Multivariate modeling confirmed rupture status (P = .003, hazard ratio = 0.14) and aneurysm dome width (P = .005, hazard ratio = 1.23) as independent predictors of progression requiring retreatment. In a separate multivariate analysis with ACoA and MCA aneurysms, basilar tip location was an independent predictor of progression, retreatment, and retreated progression.
CONCLUSION: BTAs have higher rates of progression and retreated progression than other aneurysm locations, independent of treatment modality. Rupture status and dome width are risk factors for progression requiring retreatment.
Copyright © 2018 by the Congress of Neurological Surgeons.

Entities:  

Keywords:  Basilar tip aneurysm; Progression; Recanalization; Recurrence; Retreatment

Year:  2019        PMID: 29905850     DOI: 10.1093/ons/opy132

Source DB:  PubMed          Journal:  Oper Neurosurg (Hagerstown)        ISSN: 2332-4252            Impact factor:   2.703


  5 in total

1.  Treatment of Wide-Neck Intracranial Aneurysms with the Woven EndoBridge Device Associated with Stenting: A Single-Center Experience.

Authors:  F Cagnazzo; R Ahmed; C Dargazanli; P-H Lefevre; G Gascou; I Derraz; S A Kalmanovich; C Riquelme; A Bonafe; V Costalat
Journal:  AJNR Am J Neuroradiol       Date:  2019-04-11       Impact factor: 3.825

2.  Comparison of angiographic outcomes and complication rates of WEB embolization and coiling for treatment of unruptured basilar tip aneurysms.

Authors:  Erkan Celik; Yigit Ozpeynirci; Thomas Liebig; Marc Schlamann; Franziska Dorn; Nils Lehnen; Eberhard Siebert; Lukas Goertz; Christoph Kabbasch
Journal:  Sci Rep       Date:  2022-06-28       Impact factor: 4.996

3.  Three-dimensional aneurysm volume measurements show no correlation between coil packing density and recurrence.

Authors:  Bart Thaci; Miriam Nuño; Kunal Varshneya; Clayton H Gerndt; Matthew Kercher; Brian C Dahlin; Ben Waldau
Journal:  Heliyon       Date:  2020-10-08

4.  Woven Endobridge (WEB) augmented by Y-stent in a shallow basilar tip aneurysm.

Authors:  Nathan J Nordmann; Matthew W Weber; Hayan Dayoub
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2022-02-17

5.  Endovascular Treatment of Small Ruptured Intracranial Aneurysms (<5 mm) : Long-term Clinical and Angiographic Outcomes and Related Predictors.

Authors:  Fei Peng; Xin Feng; Xin Tong; Baorui Zhang; Luyao Wang; Erkang Guo; Peng Qi; Jun Lu; Zhongxue Wu; Daming Wang; Aihua Liu
Journal:  Clin Neuroradiol       Date:  2019-11-06       Impact factor: 3.649

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.